GradedCalls Analysts
Loading the ledger…
GradedCalls Analysts
Loading the ledger…
NYSE · Healthcare
Eli Lilly · Pharmaceuticals. Historical grades below use the calls in this ledger. The list is each analyst’s latest recommendation. The bar under it is the direction for grading, not a live street tally.
Direction for grading, from the latest active call of each analyst. Strong Buy, Buy, Overweight, and Outperform count as Buy. Hold, Neutral, and Equal-Weight count as Hold. Underperform, Underweight, and Sell count as Sell. The recommendation on the call — Target raise, Upgrade to Buy, Reiterate Overweight — is a separate label.
Overall factor · 2W
48.7/100Average of active call grades
GC score5/10GC 1→GC 10
GC 5–7. From 40 up to 70 is PROVISIONAL on the GC Scale.
The overall factor is the average of the 0–100 grades on active calls at this horizon. A call superseded by a later note on the same ticker within 90 days stays visible and does not enter this average, the GC score, or the hit rate. How this is computed
Active graded
| Analyst | Firm | N | Hit | Overall factor/100 · GC 1–10 |
|---|---|---|---|---|
| Mohit Bansal | Wells Fargo | 1 | 100% | 74/1008/10 |
| Courtney Breen | Bernstein | 1 | 100% | 70/1008/10 |
| Geoff Meacham | Citi | 1 | 100% | 70 |
These calls count toward the overall factor once the horizon has a price. An open window is listed and is not in the average yet.
| Date | Analyst | Recommendation | Directionfor grading | Target | Then | After | Return | Grade |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 Supersedes Supersedes prior call on Aug 6, 2026 (within 90 days). Prior call | Carter GouldCantor | Target raise Desk rating stays Overweight | Buy | — | — | |||
| Oct 7, 2026 |
8
In this factor
Superseded
3
Visible, not scored
Hit rate
63%
Active calls only
If followed
+2.6%
Active directional calls
Active calls on LLY were a full hit 63% of the time. Hit rate is not the rank.
| Michael Yee | UBS | 1 | 100% | 70/1008/10 |
| Robyn Karnauskas | Truist | 1 | 100% | 70/1008/10 |
| Jason Gerberry | BofA | 1 | 0% | 35/1004/10 |
| Steve Scala | TD Cowen | 1 | 0% | 0.5/1001/10 |
| Seamus Fernandez | Guggenheim | 1 | 0% | 0/100—/10 EXIT LIQUIDITY |
| Terence FlynnMorgan Stanley |
| Target raise Desk rating stays Overweight |
| Buy |
| — |
| — |
| Sep 22, 2026 | Steve ScalaTD Cowen | Reiterate Buy Desk rating stays Buy | Buy | $1,157.49 | -1.1% | Miss |
| Sep 18, 2026 Supersedes Supersedes prior call on Jul 13, 2026 (within 90 days). Prior call | Seamus FernandezGuggenheim | Target raise Desk rating stays Buy | Buy | $1,142.85 | -0.9% | Miss |
| Aug 7, 2026 Supersedes Supersedes prior call on Jul 8, 2026 (within 90 days). Prior call | Robyn KarnauskasTruist | Target raise Desk rating stays Buy | Buy | $1,255.40 | +6.0% | Hit |
| Aug 6, 2026 | Mohit BansalWells Fargo | Target raise Desk rating stays Overweight | Buy | $1,244.40 | +4.6% | Hit |
| Jul 15, 2026 | Geoff MeachamCiti | Target raise Desk rating stays Buy | Buy | $1,208.29 | +4.6% | Hit |
| Jul 14, 2026 | Courtney BreenBernstein | Target raise Desk rating stays Outperform | Buy | $1,218.91 | +5.9% | Hit |
| Jul 13, 2026 | Michael YeeUBS | Target raise Desk rating stays Buy | Buy | $1,195.82 | +1.3% | Hit |
| Jul 10, 2026 | Jason GerberryBofA | Target raise Desk rating stays Buy | Buy | $1,194.32 | +0.6% | Near |
History only. A later call on the same ticker within 90 days replaced these. The notes stay. They do not enter the overall factor.
| Date | Analyst | Recommendation | Directionfor grading | Target | Then | After | Return | Grade |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 Nullified Nullified — superseded by later call on Oct 8, 2026 (within 90 days). Later call | Carter GouldCantor | Target raise Desk rating stays Overweight | Buy | $1,244.40 | +4.6% | Hit Not scored | ||
| Jul 13, 2026 Nullified Nullified — superseded by later call on Sep 18, 2026 (within 90 days). Later call | Seamus FernandezGuggenheim | Target raise Desk rating stays Buy | Buy | $1,195.82 | +1.3% | Hit Not scored | ||
| Jul 8, 2026 Nullified Nullified — superseded by later call on Aug 7, 2026 (within 90 days). Later call | Robyn KarnauskasTruist | Target raise Desk rating stays Buy | Buy | $1,161.35 | -4.3% | Miss Not scored |